Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive April 1, 2007 Porth & Sillup	Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news.
Pharmaceutical Executive March 1, 2009 Porth & Sillup	Fifth Annual Press Audit: Safety in the Spotlight Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety and the regulators who enforce it.
Pharmaceutical Executive March 1, 2013 Sillup et al.	Back in the News Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues.
Pharmaceutical Executive March 1, 2012 Sillup & Porth	Pharma & The Press Our eighth annual press audit finds the industry out of the crosshairs for now.
Pharmaceutical Executive March 3, 2014 Sillup & Porth	Pharm Exec: Annual Press Audit 2014 Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years.
Pharmaceutical Executive March 1, 2011	Pharm Exec's Seventh Annual Media Audit Negative views regarding pharma are on the rise, but vaccines help keep the focus on the positives of innovation.
Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
Pharmaceutical Executive April 1, 2011	Revisiting Reform Courts, Congress review policies and programs shaping drug costs and access.
Pharmaceutical Executive March 1, 2011 William Looney	John Castellani: Industry's Level Bet on a Dizzying Future Can PhRMA's own business model sync with industry's Pharm Exec takes a closer look at PhRMA's new leadership.
Pharmaceutical Executive June 1, 2007 Stan Bernard	Consumerization: Pandora's Pillbox By going direct-to-consumer, the industry unwittingly unleashed a swarm of opportunities for other players to enter the pharmaceutical fray. And they made the most of it. Now, a decade later, pharma is feeling the fallout in consumer trust and product value. It's time to take back control.
Pharmaceutical Executive January 1, 2013 Jill Wechsler	Transformation to Characterize 2013 FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.
Pharmaceutical Executive December 1, 2008 Jill Wechsler	Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers.
Chemistry World November 23, 2011 Helen Carmichael	Nanotechnology risks get minimal press coverage A US study has found scant media coverage of the potential risks posed by nanotechnology, with many more articles extolling its future benefits.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
Pharmaceutical Executive October 1, 2008 Jill Wechsler	Part D Under Attack Congressional leaders ready campaign to curb Medicare drug plans.
Pharmaceutical Executive April 10, 2014	Obama Policies Reshape Pharma Marketing Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.
Managed Care April 2001 Patrick Mullen	Interview: Alan F. Holmer With the ever-rising cost of prescription drugs generating an outcry to reform Medicare, PhRMA's president finds himself in the eye of the storm...
Pharmaceutical Executive February 1, 2011 Jon Zifferblat	China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country
Search Engine Watch August 2, 2000 Danny Sullivan	Breaking The News Barrier Moreover and Yahoo go a step ordinary news search engines, because they pick up headlines from subject-oriented sites that even news search engines may miss. Those interested in news should try either Moreover or Yahoo, because of the breadth of coverage they offer.
Pharmaceutical Executive February 1, 2006 Chandler & Chicco	Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways
Pharmaceutical Executive December 1, 2012 Jill Wechsler	Obamacare, Innovation and Pricing Tax and budget decisions will shape the healthcare market and drug research and regulation.
Pharmaceutical Executive February 1, 2012 Jill Wechsler	Costs and Benefits of Health Reform Will expanded markets and accountable care organizations offset higher rebates, added fees, and closer scrutiny of marketing and prices?
Pharmaceutical Executive November 1, 2005 Jill Wechsler	Washington Report: Out of Commission? Crawford Steps Down The clouded circumstances of the commissioner of the Food and Drug Administration may complicate the process of securing a permanent leader. Meanwhile, battles continue over hot-button issues such as the morning-after pill and the regulation of follow-on biologics.
ONLINE Jul/Aug 2012 Sarah L. Elichko	Triage, Treat, Release: Finding Medical Information Using MedlinePlus and PubMed Emergency rooms have instituted a protocol called Triage, Treat, Release to care for patients presenting with minor injuries. It's also an apt metaphor for librarians helping patrons to find information, whether the reference desk is physical or virtual.
Pharmaceutical Executive July 1, 2005 Sarah Wealleans	Up in Smoke Pharma needs to learn a few lessons in how to respond when attacked. Maybe it's time to pay attention to the experience of an industry that's had more practice than anybody: tobacco.
Pharmaceutical Executive February 1, 2006 Peter Pitts	Opinion: The Media Attacks Ghostwritten Articles Is it right and appropriate for pharmaceutical companies to be involved in the drafting of medical journal articles that are based on their own studies of their own products.
Pharmaceutical Executive April 1, 2005	Thought Leader: Better Business: Balancing Benefit, Risk, and Cost An interview with author and Harvard Medical School professor Dr. Jerry Avorn on how losing track of patient welfare and failing to address important safety problems isn't just bad science and bad ethics, it's also bad business.
Pharmaceutical Executive December 1, 2005 Patrick Clinton	PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products.
Pharmaceutical Executive May 1, 2009	Ad(Ventures) in Pharmaland Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration.
Pharmaceutical Executive November 1, 2014 Jill Wechsler	Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.
Pharmaceutical Executive August 1, 2008	Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how.
Pharmaceutical Executive October 1, 2005 Andy Bender	Orchestrating Compliance Product managers at pharmaceuticals are not always happy to see their compliance officers. That may be changing.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Pharmaceutical Executive December 1, 2006 Rod Cavin	Forecasting Medicare: Price Controls in the Years Ahead Part D in 2010 will be under price and access pressure. Pharma should develop plans for the future by imagining best- and worst-case scenarios.
Pharmaceutical Executive June 1, 2005 Zimmerman & Fay	Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole.
Pharmaceutical Executive June 1, 2005 Joanna Breitstein	Turn the Page Changes in ethics and expectations are driving the way pharma interacts with medical publishers.
Pharmaceutical Executive January 1, 2012 Jill Wechsler	New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Pharmaceutical Executive May 1, 2014 Jill Wechsler	Reimbursement Limits Threaten Drug Access High cost-sharing, narrow formularies create problems for pharma companies and patients.
Investment Advisor July 1, 2011 Bill Bongiorno	Summer Doldrums? Time to Grow Through Media Exposure Take advantage of down time this summer and market your firm to the media.
Pharmaceutical Executive December 1, 2010 Jill Wechsler	New Ballgame in Washington Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research
Pharmaceutical Executive May 1, 2006 Huang, Pesile & Mozeson	Medicare Part D: D for Doomed? New drug coverage plans cost more money and serve fewer patients than the government expected. What if things get worse? Here are two scenarios for disaster.
Pharmaceutical Executive June 1, 2005 Jill Wechsler	Washington Report: "D" Is for Data It is critical for Medicare to address important questions on drug safety and utilization, and about how prescribing decisions affect health outcomes and costs.
Managed Care December 2000 Bob Carlson	3 New England States Prescribe Innovative Ways To Cut Drug Prices It's too soon to tell whether Maine's prescription drug price control law will survive a legal challenge by drug makers. But private efforts and another innovative strategy -- a plan by Maine, Vermont, and New Hampshire to purchase prescription drugs jointly -- are moving ahead...
Pharmaceutical Executive January 1, 2007 Glass & Poli	Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges.
Pharmaceutical Executive July 3, 2007 Humphrey Taylor	Opinion: Lead, Follow, or Get Out of the Way A comparative-effectiveness board is coming. The pharmaceutical industry's wise will embrace the change.
Pharmaceutical Executive January 1, 2011 Jill Wechsler	Politics & PDUFA Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead.
Pharmaceutical Executive April 1, 2011	How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry.
Pharmaceutical Executive September 1, 2012 Jill Wechsler	Costs, Coverage, and Court Decisions Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.